EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD
Image
Cannabis News
February 26, 2025
Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other neuropsychiatric disorders, potentially offering new therapeutic avenues for
Read more on Benzinga
Read More: EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD
Comments are closed, but trackbacks and pingbacks are open.